Abo Bibliothek: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 1045-4403

ISSN Online: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

The Cellular and Clinical Parameters of Anabolic Therapy for Osteoporosis

Volumen 13, Ausgabe 1, 2003, 14 pages
DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i1.30
Get accessGet access

ABSTRAKT

A new era in the management of osteoporosis began with the recent approval of parathyroid hormone (PTH) for the treatment of postmenopausal osteoporosis. This peptide holds promise as the first in a series of anabolic growth factors that promote bone formation, enhance mineralization, and stimulate periosteal growth, yet exert relatively limited effects on bone resorption. Daily intermittent PTH treatment for postmenopausal women results in a dramatic increase in bone mineral density (BMD) (i.e., 10–15% improvement in spine BMD) and a significant decline (i.e., a risk reduction of nearly 2/3) in the occurrence of fragility fractures. The mechanism of PTH’s anabolic action on the skeleton is complex and involves multiple pathways linked to common signaling peptides that affect gene transcription in osteoblasts. One fascinating aspect of PTH, both at the clinical and molecular level, is the relationship between the frequency of PTH treatment and the bone response. Depending on the type of PTH exposure, there can be an anabolic or catabolic skeletal phenotype that can then be recapitulated by certain in vivo and in vitro model systems. Transcriptional events following ligand binding to the PTH/PTHrP1 receptor have been studied, with particular interest in target genes such as IGF-I that can regulate both bone formation and resorption. Novel in vivo strategies, including temporal and conditional mutagenesis, will almost certainly lead to newer therapeutic paradigms for the treatment of postmenopausal osteoporosis.

REFERENZIERT VON
  1. Phelps E., Bezouglaia O., Tetradis S., Nervina J. M., Parathyroid Hormone Induces Receptor Activity Modifying Protein-3 (RAMP3) Expression Primarily Via 3′,5′-Cyclic Adenosine Monophosphate Signaling in Osteoblasts, Calcified Tissue International, 77, 2, 2005. Crossref

  2. Elis Sebastien, Courtland Hayden-William, Wu Yingjie, Fritton J Christopher, Sun Hui, Rosen Clifford J, Yakar Shoshana, Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact, Journal of Bone and Mineral Research, 25, 9, 2010. Crossref

  3. Jódar-Gimeno Esteban, Full length parathyroid hormone (1?84) in the treatment of osteoporosis in postmenopausal women, Clinical Interventions in Aging, 2, 1, 2007. Crossref

  4. Lyritis George P., Georgoulas Thomas, Zafeiris Christos P, Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis, Annals of the New York Academy of Sciences, 1205, 1, 2010. Crossref

  5. Lian Jane B., Stein Gary S., Javed Amjad, van Wijnen Andre J., Stein Janet L., Montecino Martin, Hassan Mohammad Q., Gaur Tripti, Lengner Christopher J., Young Daniel W., Networks and hubs for the transcriptional control of osteoblastogenesis, Reviews in Endocrine and Metabolic Disorders, 7, 1-2, 2006. Crossref

  6. Segovia-Silvestre T., Neutzsky-Wulff A. V., Sorensen M. G., Christiansen C., Bollerslev J., Karsdal M. A., Henriksen K., Advances in osteoclast biology resulting from the study of osteopetrotic mutations, Human Genetics, 124, 6, 2009. Crossref

  7. Gazzerro Elisabetta, Canalis Ernesto, Skeletal actions of insulin-like growth factors, Expert Review of Endocrinology & Metabolism, 1, 1, 2006. Crossref

  8. Centrella Michael, Christakos Sylvia, McCarthy Thomas L., Skeletal hormones and the C/EBP and Runx transcription factors: interactions that integrate and redefine gene expression, Gene, 342, 1, 2004. Crossref

  9. McCarthy Thomas L., Kallen Caleb B., Centrella Michael, β-Catenin independent cross-control between the estradiol and Wnt pathways in osteoblasts, Gene, 479, 1-2, 2011. Crossref

  10. Girotra Monica, Cosman Felicia, Bilezikian John P., Treatment of Male Osteoporosis with Parathyroid Hormone, in Osteoporosis in Men, 2010. Crossref

  11. LIAN JANE B., STEIN GARY S., The Cells of Bone, in Dynamics of Bone and Cartilage Metabolism, 2006. Crossref

  12. Zhou Fangfang, Huang Huizhe, Zhang Long, Bisindoylmaleimide I enhances osteogenic differentiation, Protein & Cell, 3, 4, 2012. Crossref

  13. Capriani Cristiana, Irani Dinaz, Bilezikian John P, Safety of osteoanabolic therapy: A decade of experience, Journal of Bone and Mineral Research, 27, 12, 2012. Crossref

  14. Aubin Jane E., Mesenchymal Stem Cells and Osteoblast Differentiation, in Principles of Bone Biology, 2008. Crossref

  15. Liu Yan-Qiu, Han Xiao-Fei, Liu Tiegang, Cheng Meng-Chun, Xiao Hong-Bin, A cell-based model of bone remodeling for identifying activity of icarrin in the treatment of osteoporosis, Biotechnology Letters, 37, 1, 2015. Crossref

  16. Schultz Thomas C, Valenzano Jonathan P, Verzella Jessica L, Umland Elena M, Odanacatib: An Emerging Novel Treatment Alternative for Postmenopausal Osteoporosis, Women's Health, 11, 6, 2015. Crossref

  17. Echeverri A.F., Ospina F.E., Cañas C.A., Agualimpia A., Suso J.P., Tobón G.J., Bonilla-Abadía F., Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients, British Journal of Dermatology, 175, 5, 2016. Crossref

  18. Htet T. D., Eisman J. A., Elder G. J., Center J. R., Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide, Osteoporosis International, 29, 2, 2018. Crossref

  19. Hsu Jeffrey J., Lu Jinxiu, Umar Soban, Lee Jason T., Kulkarni Rajan P., Ding Yichen, Chang Chih-Chiang, Hsiai Tzung K., Hokugo Akishige, Gkouveris Ioannis, Tetradis Sotirios, Nishimura Ichiro, Demer Linda L., Tintut Yin, Effects of teriparatide on morphology of aortic calcification in aged hyperlipidemic mice, American Journal of Physiology-Heart and Circulatory Physiology, 314, 6, 2018. Crossref

  20. Teplyuk Nadiya M., Zhang Ying, Lou Yang, Hawse John R., Hassan Mohammad Q., Teplyuk Viktor I., Pratap Jitesh, Galindo Mario, Stein Janet L., Stein Gary S., Lian Jane B., van Wijnen Andre J., The Osteogenic Transcription Factor Runx2 Controls Genes Involved in Sterol/Steroid Metabolism, Including Cyp11a1 in Osteoblasts, Molecular Endocrinology, 23, 6, 2009. Crossref

  21. Hock J. M., Basic Aspects of PTH in Skeletal Health, in Osteoporosis, 2010. Crossref

  22. Clemmons David R., Insulin-Like Growth Factor-1 and Its Binding Proteins, in Endocrinology, 2010. Crossref

  23. Yamaguchi Masayuki, Ogata Naoshi, Shinoda Yusuke, Akune Toru, Kamekura Satoru, Terauchi Yasuo, Kadowaki Takashi, Hoshi Kazuto, Chung Ung-Il, Nakamura Kozo, Kawaguchi Hiroshi, Insulin Receptor Substrate-1 Is Required for Bone Anabolic Function of Parathyroid Hormone in Mice, Endocrinology, 146, 6, 2005. Crossref

  24. McCarthy Thomas L., Clough Mary E., Gundberg Caren M., Centrella Michael, Expression of an estrogen receptor agonist in differentiating osteoblast cultures, Proceedings of the National Academy of Sciences, 105, 19, 2008. Crossref

  25. Teplyuk Nadiya M., Galindo Mario, Teplyuk Viktor I., Pratap Jitesh, Young Daniel W., Lapointe David, Javed Amjad, Stein Janet L., Lian Jane B., Stein Gary S., van Wijnen Andre J., Runx2 Regulates G Protein-coupled Signaling Pathways to Control Growth of Osteoblast Progenitors, Journal of Biological Chemistry, 283, 41, 2008. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain